BioNTech Shares Fall Roughly 7% After BNT113 Trial Miss
BioNTech shares closed down roughly 7% Tuesday after its investigational mRNA cancer immunotherapy BNT113 failed to show a statistically significant progression-free survival benefit in a late-stage trial. An analyst linked the result to broader mRNA cancer-vaccine struggles.